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Several lines of evidence indicate that mutations in the GBA
gene coding for glucocerebrosidase (Glucosylceramidase,
GCase) contribute to the development of Parkinson’s disease
(PD) and dementia with Lewy bodies (DLB); however, the
underlying mechanism is still to be established. Whilst there
is a variable strength of association in certain populations, a
large meta-analysis has demonstrated the odds ratio for any
GBA mutation in patients versus controls to be 5.43 across
centres, providing validation of GBA as a risk gene for PD
(Sidransky et al. 2009). GBA-associated parkinsonism seems
to be characterized by an earlier onset and an increased
likelihood of cognitive decline and dementia, compared with
typical PD (Neumann et al. 2009; Sidransky et al. 2009;
Seto-Salvia et al. 2012). Features typical of DLB also cluster
with GBA-associated phenotypes (Goker-Alpan et al. 2008)
and population studies have shown an increased frequency of
GBA mutations in DLB as in PD (Goker-Alpan et al. 2006;
Mata et al. 2008). DLB, PD and PD with dementia (PDD)
belong to the common spectrum of Lewy body disease
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Abstract
Lewy body disease (LBD) development is enhanced by
mutations in the GBA gene coding for glucocerebrosidase
(GCase). The mechanism of this association is thought to
involve an abnormal lysosomal system and we therefore
sought to evaluate if lysosomal changes contribute to the
pathogenesis of idiopathic LBD. Analysis of post-mortem
frontal cortex tissue from 7 GBA mutation carriers with LBD, 5
GBA mutation carriers with no signs of neurological disease
and human neural stem cells exposed to a GCase inhibitor
was used to determine how GBA mutation contributes to LBD.
GBA mutation carriers demonstrated a significantly reduced
level of GCase protein and enzyme activity and retention of
glucocerebrosidase isoforms within the endoplasmic reticulum
(ER). This was associated with enhanced expression of the
lysosomal markers LAMP1 and LAMP2, though the expres-
sion of ATP13A2 and Cathepsin D was reduced, along with
the decreased activity of Cathepsin D. The ER unfolded pro-
tein response (UPR) regulator BiP/GRP78 was reduced by
GBA mutation and this was a general phenomenon in LBD.
Despite elevation of GRP94 in LBD, individuals with GBA
mutations showed reduced GRP94 expression, suggesting an
inadequate UPR. Finally, human neural stem cell cultures
showed that inhibition of GCase causes acute reduction of
BiP, indicating that the UPR is affected by reduced gluco-
cerebrosidase activity. The results indicate that mutation in
GBA leads to additional lysosomal abnormalities, enhanced
by an impaired UPR, potentially causing a-synuclein accu-
mulation.
Keywords: dementia with Lewy bodies, endoplasmic reticu-
lum, glucocerebrosidase, Lewy body disease, lysosome,
Parkinson’s disease.
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(LBD), as they are characterized by the overlapping clinical
symptoms reflecting the common pathogenesis, i.e. the
dismetabolism of a-synuclein and formation of Lewy bodies
in the brain (Lippa et al. 2007). Mutant GCase, therefore,
may be a contributory factor to the development of Lewy
body disease in general.
Homozygous mutations in the GBA gene cause Gaucher’s
disease (GD), the most prevalent lysosomal storage
disorder, due to deficiency of glucocerebrosidase activity,
and the accumulation of its main substrate glucocerebroside
(D-glucosyl-N-acylsphingosine, glucosylceramide) in lyso-
somes in macrophages (Barranger and Ginns 1989). GD
patients present a wide spectrum of clinical phenotypes with
three subtypes of GD; type 1–non-neuronopathic
(MIM:230800), type 2–acute neuronopathic (MIM:230900)
and type 3–subacute neuronopathic (MIM:2301000) with
involvement of the nervous system in type 2 and 3, in
contrast to type 1 (Barranger and Ginns 1989). Early-onset
parkinsonism has also been associated with GD. Initial
reports described mild late-onset GD patients with typical
PD that included tremor, bradykinesia, rigidity and often
cognitive decline, with a poor response to conventional anti-
parkinsonian therapy (Neudorfer et al. 1996), with typical
neuropathological changes (Wong et al. 2004). A family
history of parkinsonism in GD probands has also been
reported, demonstrating the potential predisposition of GBA
heterozygotes to parkinsonism (Goker-Alpan et al. 2004).
The presence of glucocerebrosidase in Lewy bodies and
Lewy neurites in patients carrying GBA mutations suggests
that glucocerebrosidase can contribute to the aggregation of
a-synuclein and Lewy body formation (Goker-Alpan et al.
2010). Increased a-synuclein immunoreactivity has been
observed in cells treated with conduritol B epoxide (CBE),
an inhibitor of GCase activity, along with accumulation of
a-synuclein within the substantia nigra in CBE-treated mice
(Manning-Bog et al. 2009). This indicates that reduced
glucocerebrosidase activity may promote alterations in
a-synuclein biology and these changes are also present in
the brains of mice and in neuronal cells carrying GBA
mutations (Cullen et al. 2011; Mazzulli et al. 2011; Sardi
et al. 2011). It is plausible that mutant glucocerebrosidase
interferes with cellular clearance of a-synuclein via lyso-
somal pathway and stimulates protein aggregation (Cuervo
et al. 2004; Mazzulli et al. 2011), thus predisposing to the
development of synucleinopathies.
To gain an insight into the effects of glucocerebrosidase on
neuronal function, we aimed to evaluate the effects of mutant
GBA gene in human frontal cortex tissue by examining
glucocerebrosidase protein levels and activities in GBA
mutation carriers and establishing whether lysosomal
changes were evident. Furthermore, a hypothesis, that the
presence of misfolded proteins, perhaps glucocerebrosidase,
in the ER induces ER stress and contributes to the
development of LBD, was also explored.
Materials and methods
Case control analysis
All procedures were approved by the Local Research Ethics
Committee. A prospective clinicopathological series of patients
with DLB (n = 105) or PD (n = 79) fulfilling clinical and
neuropathological criteria (Gibb and Lees 1988; McKeith et al.
1996; McKeith 2006) was screened for mutations in GBA. PD and
DLB cases were grouped together as LBD since pathological
changes were similar, clinical presentation differing only in the
timing of any dementia in relation to PD. A cohort of elderly
normal individuals (n = 164 pathologically confirmed) without a
history of neurological or psychiatric impairment was also
genotyped and used as a control population. DNA was extracted
from frozen post-mortem brain tissue using standard methods.
Seven specific mutations in GBA were identified and screened
using PCR-RFLP-based assays and cycle sequencing (see Table 1
for case details and Table S1).
Tissue analysis
Post-mortem frontal cortex (Brodmann Area 8) tissue was used as an
area relatively spared from major LBD pathology and cell loss,
which may confound studies in regions such as substantia nigra.
GBA mutation being present in all cells would be expected to have
effects in most cell types. Tissue from individuals identified from
the cohort as carrying GBA mutations (4 DLB, 3 PD and 5 controls)
and non-carriers (7 DLB, 8 PD and 11 controls) was rapidly thawed
and approximately 250 mg of grey matter homogenized over ice
using a rotor stator-type homogenizer in 10 volumes of 0.32 M
sucrose, 1 mM EDTA, 50 mM Tris, pH 7.4 (Sigma, Gillingham,
Dorset, UK), protease inhibitor cocktail tablets EDTA-free (Roche,
Burgess Hill, West Sussex, UK) containing buffer. After addition of
Triton X-100 (Sigma) to a final concentration of 1%, samples were
sonicated for 20 min on ice in a sonicating bath. Another subset of
four human spleen and four frontal cortex tissue samples (30–
180 mg wet tissue) were homogenized as previously. Triton X-100
was then added to a final concentration of 1%, followed by
incubation on ice for 30 min and centrifugation at 25 200 g for
60 min. Supernatants were subjected to the further analysis as Triton
X-100-soluble fractions. Protein concentration was determined
using Bradford assay.
GCase enzymatic activity
To investigate the effects of GBA mutation on brain enzyme activity,
a standard glucocerebrosidase activity assay at acidic pH was
employed. Residual enzyme activity was determined as the produc-
tion of fluorescent 4-methylumbelliferone (4-MU) from 4-methyl-
umbelliferyl-b-D-glucopyranoside (4-MUG) substrate as described
previously (Takagi et al. 1999). Sample triplicates, each containing
50 lg protein (brain homogenates) or 10 lg protein (cell lysates)
were diluted in assay buffer of 50 mM citrate phosphate buffer, pH
5.0 and 0.25% sodium taurocholate (Sigma) containing 0.5 mM 4-
MUG in 96-well black polystyrene plates. The reactions were
incubated at 37°C for 1–2 h and terminated by addition of 200 lL of
200 mM carbonate-bicarbonate buffer, pH 10.5. Fluorescence was
measured (Ex 360 nm, Em 460 nm) and a 4-MU standard solution
(0–4000 nM) was used to generate a standard curve. Control of
glucocerebrosidase inhibition was carried out with the addition of
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100 lM of the specific glucocerebrosidase inhibitor CBE (Sigma),
which reduced activity to approximately 15% of total values.
Western blot analysis
Samples of brain tissue homogenates and cell lysates containing
10 lg of protein were resolved by electrophoresis on 10% or 4–12%
sodium dodecyl sulphate–polyacrylamide gels (Invitrogen, Paisley
UK), and transferred to nitrocellulose membranes using iBlot Gel
Transfer Stacks (Invitrogen). The membranes were probed with
primary and secondary antibodies (see Table S2) using standard
methods and developed using Amersham ECL detection reagents
(GE Healthcare, Buckinghamshire, UK) and exposed to autoradi-
ography film (Kodak, Sigma, Gillingham, Dorset, UK). The blots
were scanned and band intensities were analysed using ImageJ
software. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
was used to normalize the results and the ratios of mean protein/
GAPDH were calculated. The results are presented as mean ± SD.
Endo-H and PNGase F treatment
To determine the effects of GBA mutation on glucocerebrosidase
glycosylation and oligosaccharide chain development, either Endo-
glycosidase H, to strip proteins of high mannose oligosaccharides
[complex oligosaccharides are resistant to Endoglycosidase-H
(Endo-H) activity], or Peptide N glycosidase F (PNGase F), to
remove all types of asparagine N-linked oligosaccharides, was used.
Frontal cortex tissue homogenates or spleen and frontal cortex
Triton X-100-soluble fractions, containing 20 lg of protein, were
treated with either PNGase F or Endo-H (New England Biolabs,
Hitchin, Herts., UK) according to the manufacturer’s instructions.
Treated samples and non-treated controls were resolved using 4–
12% sodium dodecyl sulphate–polyacrylamide gels (Invitrogen) and
analysed by Western blot.
Cathepsin D enzymatic activity
The residual Cathepsin D activity was measured in the human brain
tissue samples using a kinetic assay (Yasuda et al. 1999). Cathepsin
D substrate solution (Enzo Life Sciences, Exeter, UK) was used at a
final concentration of 20 lM. Pepstatin A (Enzo Life Sciences)
solution at a final concentration of 0.2 mg/mL was used for the
selective inhibition of Cathepsin D. Briefly, 5 lg of protein samples
(prepared in native lysis buffer containing 0.32 M Sucrose, 1 mM
EDTA, 50 mM Tris, pH 7.4 (all Sigma) and EDTA-free protease
inhibitor cocktail tablets (Roche)) were diluted in an assay buffer
(50 mM sodium acetate buffer, pH 4.0 (Sigma)) in a final volume of
10 lL. In 96-well black polystyrene plates, 40 lL of the assay
buffer or for the control samples with inhibitor, 40 lL of Pepstatin
A solution in the assay buffer were added to the protein samples and
pre-incubated at 37°C for 10 min and subsequently, 50 lL of the
substrate solution in the assay buffer pre-heated to 37°C were added
to all samples. The increase in fluorescence was measured (Ex
320 nm, Em 400 nm, sensitivity 100, 37°C). For 30-min incubation,
the readings were taken at intervals of 5 min. 7-methoxycoumarin-
4-acetic acid (Sigma) in the assay buffer (0–1.5 nmoles (0–15 lM))
was used to generate a standard curve. Pepstatin A caused a
complete inhibition of enzyme activity.
Human neural stem cell cultures
Human neural precursor stem cell lines were grown as neurospheres
according to previously described methods (Burnstein et al. 2004) at
37°C in a 95% air/5% CO2, humidified incubator. Proliferation
medium was replenished at 2–3-day intervals by replacing 60–70%
of the medium with fresh medium. For assay, cells were extensively
triturated to small neurospheres and seeded into 25 cm flasks coated
with 0.5% gelatine (Sigma) and grown for 10 days. Growth medium
was replaced with differentiating medium containing Dulbecco’s
modified Eagle’s medium /F12 supplemented with 10% heat-
inactivated Foetal Bovine Serum (Sigma), N-1, B27 and N-2.
Conversion of neurospheres into cells with neural morphology took
2–3 days. Cells were allowed to grow for a further 14 days to
develop neuritic networks after which they were treated for
72 h with 100 lM CBE or dimethyl sulfoxide (0.02%) vehicle.
Cells were lysed using ice-cold native lysis buffer [Tris-buffered
saline containing 0.32 M Sucrose, 1% Triton X-100 (all Sigma),
1 · protease/phosphatase inhibitor cocktail (Roche)] and sonicated
Table 1 Case details of mutation-carrying donor samples
Patient GBA mutation Clinical diagnosis Gender AAO-Dem (years) AAO-PD (years) Age-Death (years)
DLB_1 IVS2 + 1 DLB Female 65 Not Identifieda 71
DLB_2 RecNciI DLB Female 51 52 57
DLB_3 N370S DLB Female 74 79 82
DLB_4 L444P DLB Female 75 75 77
PD_1 IVS2 + 1 PDD Male 73 70 74
PD_2 L444P PD Male No dementia 66 70
PD_3 L105R PDD Female 76 Not known 78
C_1 RecNciI Control Female NA NA 89
C_2 N370S Control Female NA NA 86
C_3 L444P Control Female NA NA 83
C_4 N370S Control Male NA NA 55
C_5 N370S Control Male NA NA 51
aFor case DLB_1, no clinical details indicating parkinsonism could be identified on the case note review. Pathology showed widespread substantia
nigra neuron loss and cortical Lewy bodies.
AAO-Dem, Age at onset of dementia where this could be accurately ascertained; AAO-PD, Age at onset of parkinsonism movement disorder
where this could be accurately determined; NA, not applicable.
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for 20 min on ice in a sonicating bath. Subsequently, lysates were
centrifuged at 1000 g for 10 min and the supernatants subjected to
Western blotting. Protein concentration was determined using
Bradford assay. Data are the mean of three independent replicates.
Statistical analysis
F-test two-sample for variances and t-test: two-sample assuming
equal or unequal variances were used to assess statistical signifi-
cance of the enzyme activity and Western blot analysis data. For the
stem cell culture studies, the data consist of the mean of all three
independent replicates and the paired sample statistics of the three
independent experiments was performed using SPSS Statistics 17.0
(SPSS, Chicago, IL, USA). Statistical significance was considered
when p two-tail £ 0.05. Graphs were generated using GraphPad
Prism 4 software (GraphPad, San Diego, CA, USA). The results are
presented as mean ± SD. Fold changes (FC) represent: average of
ratios of mean (protein/GAPDH) for treated (mutant) samples/
average of ratios of mean (protein/GAPDH) for untreated (control)
samples.
Results
GCase activity
Brain tissue from the frontal cortex of LBD cases and
controls, both with and without GBA mutation, were
screened for the relative levels of glucocerebrosidase
protein by Western blotting (Fig 1). Analysis of relative
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Fig. 1 Peptide N-glycosidase F (PNGase F)-treated glucocerebrosi-
dase in normal and GBA mutation carriers: Brain homogenates were
treated with PNGase F to show protein molecular weight and Western
blotting for glucocerebrosidase used to detect glucocerebrosidase pro-
tein (a). The major isoform of glucocerebrosidase was reduced inGBA-
mutation heterozygotes (GBA mutations: L444P, RecNciI, IVS2 + 1
G>A, N370S and L105R) (LBDmt, n = 5; Cmt, n = 5) compared to wild-
type GBA individuals (LBDwt, n = 5; Cwt, n = 5) (b). Reductions in the
major isoform were seen irrespective of the presence of Lewy body
disease. Changes were seen in the levels of the short isoform of gluco-
cerebrosidase in controls with GBA mutations, although this was not
significant in LBD cases and GBA mutation carriers; overall, the short
isoform was significantly reduced (c). Figures are Mean GBA/GAPDH
ratio ± SD. Numbering ofmutation bearing cases is according to Table 1.
Ó 2012 The Authors
Journal of Neurochemistry Ó 2012 International Society for Neurochemistry, J. Neurochem. (2012) 123, 298–309
GCase mutations in Lewy body disease | 301
levels of glucocerebrosidase protein (following PNGase F
treatment) showed a reduction in the longer isoform of
glucocerebrosidase of approximately 20% in mutation
carriers (p < 0.05, mutant vs. wild type, LBDmt n = 5,
LBDwt n = 5, Cmt n = 5, Cwt n = 5), irrespective of
disease state, with the shorter isoform showing a reduction
in levels in the control samples carrying mutation (p < 0.05,
mutant vs. wild type), although this was not significantly
reduced in LBD cases (p > 0.05, mutant vs. wild type,
Fig 1). Alterations in GCase were not because of either
neuronal loss or gliosis as we found no significant change
in NeuN or GFAP between samples (not shown). This was
confirmed by analysis of glucocerebrosidase enzyme activ-
ity, which again showed an approximately 25% reduction in
enzyme activity in GBA mutation carriers irrespective of
disease state (Fig 2), with no reduction in activity because
of the presence of LBD. Individual analysis of specific
mutations did not show any consistent pattern of enzyme
activity reduction (not shown), although we cannot rule out
a genotype–phenotype relationship, given the reduced
numbers of cases studied.
Lysosomal markers
As glucocerebrosidase is a major lysosomal enzyme, we
tested whether the presence of reduced glucocerebrosidase
levels as a result of GBA mutation causes any change in
lysosomal composition. Using the major lysosomal mem-
brane protein (LAMP1) as a marker of lysosome mass
(Eskelinen 2006), an elevation of LAMP1 associated with
the presence of GBA mutation was seen in both normal
individuals (p < 0.05, Cmt n = 5 vs. Cwt n = 10), and in
individuals with LBD (p < 0.05, LBDmt n = 7 vs. LBDwt
n = 15), Fig 3). Similarly, LAMP2 relative protein levels
were also found to be elevated by approximately 10–15% in
GBA mutation carriers (p < 0.05, LBDmt n = 5 vs. LBDwt
n = 14; p < 0.05 Cmt n = 5 vs. Cwt n = 10). As glucocer-
ebrosidase uses LIMP-2/SCARB2 for import and sequestra-
tion by lysosomes (Reczek et al. 2007) the effects of GBA
mutation on expression were determined. Control cases
carrying GBA mutation showed significantly increased
LIMP-2 expression (p < 0.05, Cmt n = 5 vs. Cwt n = 11),
and whilst increased, this was not significant in LBD cases
with GBA mutation (0.05 < p < 0.1, LBDmt n = 7 vs.
LBDwt n = 15), Fig 3). Whilst the elevation of these major
lysosomal proteins pointed towards a general increase in
lysosomal mass, not all lysosomal proteins were increased.
Specifically, the Parkinsonism-related protein ATP13A2,
involved with Kufor–Rakeb syndrome, was reduced in LBD
GBA mutation carriers (p < 0.05, LBDmt n = 7 vs. LBDwt
n = 14), see Fig 4), as was the major lysosomal protease
Cathepsin D (Fig 4) in LBD cases (p < 0.05, LBDmt n = 7
vs. LBDwt n = 14), but not in controls carrying GBA
mutation (p > 0.05, Cmt n = 5 vs. Cwt n = 11). Consis-
tently, LBD cases with GBA mutations showed significantly
decreased activities of Cathepsin D enzyme compared with
non-carriers (15% depletion, p < 0.05, LBDmt n = 7,
LBDwt n = 15) (Figure S1). This was, however, not char-
acteristic for control individuals with GBA mutations
(p > 0.05, not significant, Cmt n = 5, Cwt n = 12). For the
individuals with no alterations in GBA, LBD patients had
significantly lower Cathepsin D activities compared with
controls (16% depletion, p < 0.05), indicating deficiency
may be more associated with LBD.
As the majority of lysosomal proteins show extensive
post-translational modification, and in particular the incor-
poration of major carbohydrate chains which aid in protein
folding and resistance to lysosomal hydrolases, we sought to
determine how glucocerebrosidase is glycosylated and the
status of the endoplasmic reticulum activity in GBA mutation
carriers. The glycosylation state of glucocerebrosidase was
investigated using Endo-H and PNGase F treatment to
remove high-mannose carbohydrate chains and all aspara-
gine N-linked oligosaccharides respectively. PNGase F
treatment of glucocerebrosidase showed the presence of
two molecular weight species of glucocerebrosidase (see
Fig 1) with evidence of glycosylation of approximately 10–
15 kDa. Frontal cortex tissue samples from GBA mutation
carriers showed significantly less cross-reacting material and
little evidence of resistance to Endo H treatment compared
with samples of human spleen, suggesting the presence of
less extensive glycosylation pattern on brain glucocerebro-
sidase (see Figure S2).
Endoplasmic reticulum markers
As there is little Endo-H-resistant glucocerebrosidase fraction
in brain which may indicate ER retention and reduced
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Fig. 2 Brain glucocerebrosidase enzyme activity is decreased in GBA
mutation carriers: Samples of grey matter (LBDmt n = 7, LBDwt
n = 15, Cmt n = 5, Cwt n = 10) were assayed for glucocerebrosidase
enzyme activity using the specific substrate and levels of 4-methyl-
umbelliferone (4-MU) production were determined. Comparison with
tissue from individuals with wild-type GBA were used as control and
showed reduced glucocerebrosidase enzyme activity in GBA mutation
carriers. Glucocerebrosidase activity was reduced in both normal and
Lewy body disease (LBD) cases to a similar extent. Note that there is
an overlap in glucocerebrosidase activity between control and mutant
samples.
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processing of glucocerebrosidase, it is possible that ER
marker proteins are altered by the presence of GBA mutation.
Western blot analysis of the major UPR protein BiP/GRP78
showed a marked reduction in LBD which was independent
of GBA mutation status, suggesting that LBD shows an
abnormal UPR (p < 0.05, LBD vs. Control, LBDmt n = 7,
LBDwt n = 15, Cwt n = 10). Analysis of control cases with
GBA mutations showed a similar reduction of BiP/GRP78 to
LBD, indicating the presence of an abnormal UPR caused by
GBA mutation (p < 0.05, Cmt n = 5 vs. Cwt n = 11), with
evidence of slightly reduced HERP (p < 0.1 > 0.05, LBDmt
n = 7 vs. LBDwt n = 13; p < 0.1 > 0.05, Cmt n = 5 vs. Cwt
n = 10), Fig 5). In contrast, the ER chaperone GRP94 was
elevated in LBD compared with controls, though this was
reduced in LBD by the presence of GBA mutation (p = 0.07,
LBDmt n = 5 vs. LBDwt n = 13) and also in controls
carrying GBA mutation (p < 0.05, Cmt n = 4 vs. Cwt
n = 11) (Fig 6). Analysis of a-synuclein levels in total brain
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Fig. 3 Major lysosomal membrane proteins
are elevated in GBA mutation carriers:
Western blotting was used to determine the
relative levels of LAMP1, LAMP2 and LIMP-
2 protein in brain homogenates from indi-
viduals with and without GBA mutations
(LBDmt n = 5–7, LBDwt n = 14–15, Cmt
n = 5, Cwt n = 10–11)(a, c). Elevated levels
of LAMP1 and LAMP2 were seen in Lewy
body disease (LBD) and normal individuals
in the presence of GBA mutation (b). The
major protein involved in import of gluco-
cerebrosidase into lysosomes LIMP-2
(SCARB2) was also seen to be elevated in
control mutation carriers (c) but was not
significantly elevated in LBD mutation car-
riers. Error bars are ± SD.
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tissue homogenates showed that the monomeric form of the
protein was elevated in LBD cases carrying GBA mutations
compared with wild-type LBD cases (p < 0.05 LBDmt n = 6
vs. LBDwt n = 11; Fig 7), whilst no alterations were
observed within controls (Cmt n = 5, Cwt n = 11).
Cell culture analysis of GBA inhibition
To determine if changes identified in the brains of GBA
mutation carriers were attributable directly to reduced
glucocerebrosidase activity, differentiated human cortical
neural stem cells were treated with the glucocerebrosidase
inhibitor, CBE. Cell extracts from treated cells showed a
slight but significant increase in glucocerebrosidase protein
(p < 0.05; Fig 8), although glucocerebrosidase activity was
almost completely inhibited (1.8% ± 0.9 of control). Acute
reduction of glucocerebrosidase activity caused a small,
however significant reduction of BiP/GRP78 protein
(p < 0.05; Fig 8), indicating similar reductions in the UPR
response to that found in tissue samples, although significant
lysosomal protein changes were not seen and no alteration in
a-synuclein was observed (data not shown).
Discussion
Previous studies in several populations have demonstrated the
association between GBA mutations and Lewy body disease
(Sidransky et al. 2009). The results of this study indicate that
GBA heterozygotes show reduced activities of glucocerebro-
sidase enzyme in the frontal cortex tissue irrespective of
disease state, consistent with previous reports (Choi et al.
2011; Mazzulli et al. 2011). This reduction in GCase enzyme
activity is relatively mild, approximately 25% in both cases
and controls carrying GBA mutation, and would suggest that
if glucocerebrosidase activity does influence development of
LBD, it does so relatively efficiently or shows a subtle effect
in concert with other mechanisms. Furthermore, the results
show a slight depletion of GCase protein in mutation carriers,
with the main isoform significantly reduced in controls and
LBD cases with GBA mutations; however, the significant
reduction of the shorter isoform was detected only in control
individuals with GBA mutation. Importantly, in neural tissue
from LBD cases and control subjects, glucocerebrosidase
appears to show little in the way of extensive glycosylation,
as evidenced by almost complete sensitivity to Endo-H
treatment in contrast to tissues such as spleen. This finding of
different patterns of glucocerebrosidase activity and process-
ing is not new (Pentchev et al. 1978; Ginns et al. 1982), but
the finding of a reduced glycosylation in the brain may have
important implications for enzyme function. Normally,
glycosylation has the effect of enhancing the folding and
solubility of a protein (Helenius and Aebi 2001) and in the
context of lysosomally directed proteins, of enhancing protein
half-life by protecting it from lysosomal proteases (Kundra
and Kornfeld 1999). An intriguing possibility is that the
preferential effects of GBA mutation on the CNS in GD on
the CNS (Sidransky 2004) may be a combination of
enhanced GCase sensitivity to lysosomal degradation
because of reduced glycosylation along with a reduced
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Fig. 4 Selective alterations in lysosomal proteins in GBA mutation
carriers with Lewy body disease: Brain tissue from GBA mutation
carriers was screened for levels of the Kufor–Rakeb Parkinsonism
protein ATP13A2 and the lysosomal protease Cathepsin D by Western
blotting (LBDmt n = 7, LBDwt n = 14, Cmt n = 5, Cwt n = 11) (a) and
relative levels determined against GAPDH levels. Reduced levels of
ATP13A2 were seen in LBD cases carrying GBA mutations but not in
normal individuals with GBA mutation (b) and similar reductions in
Cathepsin D heavy chain (28 kDa) were seen associated selectively
with LBD patients. Error bars are ± SD.
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enzyme activity because of mutation. Whilst enzyme activity
shows a relatively small change, it suggests that restoration
of activity may be a therapeutic option, particularly if blood–
brain barrier-penetrating small molecules affecting glucocer-
ebrosidase and also glucosylceramide synthase, to reduce
substrate accumulation, could be used (Mu et al. 2008;
Khanna et al. 2010; Marshall et al. 2010; Marugan et al.
2011).
Whilst the enzyme defect in glucocerebrosidase in
heterozygous carriers is modest, there appear to be
additional changes within the endoplasmic reticulum and
lysosomes. The enhanced expression of LAMP1 and
LAMP2 along with the glucocerebrosidase carrier protein
LIMP-2 indicates an abnormal cellular lysosomal activity.
The presence of abnormal lysosomal processing and
evidence of autophagy associated with synucleinopathies
is a relatively common finding (Cuervo et al. 2004; Chu
et al. 2009; Dehay et al. 2010). Whilst the enhanced
expression of LAMP1 and LAMP2 might be a response to
remove aggregated proteins and damaged organelles
(because of for example a-synuclein accumulation), this
appears to be inefficient as evidenced by the reduced
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Fig. 5 The ER Unfolded Protein Response (UPR) is abnormal in GBA
mutation carriers: The levels of ER proteins BiP/GRP78 and HERP
were determined in brain homogenates from individuals with Lewy
body disease (LBD) and in normal control individuals with and without
GBA mutations (LBDmt n = 7, LBDwt n = 13–15, Cmt n = 5, Cwt
n = 10–11) (a, c). Relative levels of BiP/GRP78 were reduced in LBD
cases, independent of mutation status, compared to controls
(p < 0.001) by approximately 10–15% but reduced in control individ-
uals (Cmt) carrying GBA mutation (b). HERP, a stress-induced ER
protein was similarly reduced in control and LBD GBA mutation car-
riers (d) although there was no change between LBD and control
samples overall (p = 0.3). Error bars are ± SD.
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Fig. 6 The chaperone GRP94 is elevated in Lewy body disease (LBD)
but reduced by GBA mutation: Brain tissue from LBD and control
individuals was probed for the major ER chaperone protein GRP94 by
Western blotting (LBDmt n = 5, LBDwt n = 13, Cmt n = 4, Cwt n = 11)
(a). Compared to controls (b) there was an elevation of GRP94 in LBD
brain of approximately 15% (p < 0.001) suggesting the presence of an
UPR, though this was reduced by the presence of GBA mutation in
controls and to a lesser extent in LBD. Error bars are ± SD.
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Fig. 7 a-synuclein is elevated in frontal cortex of GBA mutation car-
riers: Increased a-synuclein protein expression is only observed in
LBD patients with heterozygous GBA mutations and does not appear
to be elevated in normal controls with GBA mutations (total brain tis-
sue homogenates were used in the analysis) (LBDmt n = 6, LBDwt
n = 11, Cmt n = 5, Cwt n = 11).
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Cathepsin D levels and activities. The loss of lysosomal
protease activity measured as reduced Cathepsin D and
ATP13A2 protein selectively in LBD cases carrying
mutation may indicate why only some mutation carriers
develop LBD. Several studies have shown that reduced
lysosomal Cathepsin D activity can lead to a-synuclein
accumulation as can ATP13A2 reduction (Qiao et al. 2008;
Chu et al. 2009; Cullen et al. 2009; Gitler et al. 2009) and
it is possible therefore that lysosomal changes contribute to
LBD development. Given that elevated lysosome expres-
sion is evident in normal individuals heterozygous for GBA
mutations, it is possible that the lysosomal defect predis-
poses individuals to disordered protein metabolism associ-
ated with ageing, such as a-synuclein processing. The
development of LBD in individuals with heterozygous
GBA mutations may be because of additional factors such
as enhanced a-synuclein expression (Chu and Kordower
2007; Satake et al. 2009; Simon-Sanchez et al. 2009) and/
or inefficiency of protein degradation machinery (Collier
et al. 2011). The changes identified in the endoplasmic
reticulum markers of the UPR in GBA mutation carriers
and in LBD may be an indication of abnormal protein
processing associated with a-synuclein dismetabolism
(Cooper et al. 2006; Hoozemans et al. 2007). The abnor-
mal UPR in GBA mutation carriers, a finding previously
noted in animal and cell models of GD (Wei et al. 2008),
indicates that GBA mutation predisposes cells to abnormal
protein folding, exacerbated perhaps by a-synuclein accu-
mulation (Cullen et al. 2011; Sardi et al. 2011). The
reduced levels of BiP/GRP78 seen in mutation carriers and
in CBE-treated cells may predispose to neuronal cell loss
as selective knockout of BiP/GRP78 in Purkinje cells
causes neuronal cell death (Wang et al. 2010). Similarly,
the failure to mount an adequate UPR in GBA carriers
evidenced by GRP78 and GRP94 reductions may indicate
a predisposition to abnormal protein folding in GBA
mutation carriers. The current cell studies show that acute
inhibition of glucocerebrosidase function leads to ER stress
and reduced levels of BiP, although no changes in
monomeric a-synuclein levels were detected. The present
data corresponds with the previous report by Cullen et al.,
where similar concentrations of CBE were used to inhibit
GCase activity in PC12-SNCA cell lines, with no corre-
sponding a-synuclein deposition (Cullen et al. 2011). In
contrast, the initial findings by Manning-Bog et al. dem-
onstrated elevated levels of a-synuclein following CBE
exposure in SH-SY5Y cells differentiated to the neuronal
phenotype and in the substantia nigra of CBE-treated mice
(Manning-Bog et al. 2009). The predisposition of cells
carrying GCase defect to synucleinopathy might be there-
fore a combined effect of the presence of mutant GCase
protein and the loss of its enzymatic activity. It is possible
that reduced GCase activity causes ER stress and UPR
induction through abnormal lysosomal activity, which then
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Fig. 8 Effects of glucocerebrosidase inhibition in human neural cul-
tures using CBE: Differentiated human neural stem cells were ex-
posed to 100 lM of the specific glucocerebrosidase inhibitor conduritol
Beta epoxide (CBE) for 72 h and protein extracts prepared for western
blotting. CBE caused a slight elevation of steady-state levels of glu-
cocerebrosidase (a) but caused an acute change of ER stress and the
UPR as evidenced by reduced levels of BiP (b). Overall, no significant
change was seen in the major lysosomal protein LAMP1 (c). Example
blots are representative of three independent experiments. The data
presented consist of the mean of all three independent replicates.
Error bars are ± SD.
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exacerbates a-synuclein accumulation (Mazzulli et al.
2011). Alternatively, the abnormal UPR in GBA mutation
carriers identified in this study might be caused by the
enduring production of mutant GCase protein, enhanced by
ageing-related impairment of the ER chaperone systems
(Nuss et al. 2008), which may impede protein folding and
degradation (Ron et al. 2010). Prolonged activation of the
UPR leads to cell death (Tabas and Ron 2011), with nitric
oxide-mediated protein damage and polyubiquitination of
neuronal components being contributory factors (Uehara
et al. 2006), all hallmark features of LBD.
In summary, the findings of this study indicate that the
presence of glucocerebrosidase mutation rather than reduced
GCase activity may predispose neurons to the accumulation
of misfolded proteins through lysosomal abnormalities and
defects in the endoplasmic reticulum. Whilst on their own,
these changes do not appear to be associated with LBD, such
abnormalities may underlie the vulnerability of neurons to a-
synuclein dismetabolism. The small number of GBA muta-
tion-bearing LBD patients and controls analysed in this study
should be acknowledged and it may represent a limitation
factor, although various approaches were used to investigate
the potential biochemical defect in GBA heterozygotes. It
becomes apparent that LBD may be associated with a wider
spectrum of lysosomal storage disorders than GCase pathol-
ogy alone (Shachar et al. 2011; Winder-Rhodes et al. 2012),
implying that more general cellular mechanisms, as pre-
sented herein, may be involved.
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